SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER

被引：0
|
作者：
Gerber, David [1 ]
Infante, Jeffrey [2 ]
Gordon, Michael [3 ]
Schiller, Joan [1 ]
Spigel, David [4 ]
Wang, Yulei [5 ]
Shames, David S. [5 ]
Choi, Younjeong [5 ]
Kahn, Robb [5 ]
Xu, Jian [5 ]
Lin, Kedan [5 ]
Wood, Katie [5 ]
Maslyar, Daniel [5 ]
Burris, Howard [4 ]
机构：
[1] UT Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA
[2] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA
[3] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
NSCLC; ADC; Phase I; NaPi2b;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-014
引用
收藏
页码：S1190 / S1191
页数：2
相关论文
共 50 条
  • [41] TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
    Hijazo-Pechero, S.
    Alay Badosa, A.
    Vilarino, N.
    Brenes Castro, J.
    Moliner, L.
    Mosteiro, M-A.
    Vidal, N.
    Munoz-Pinedo, C.
    Bruna, J.
    Nadal, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [42] An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
    Liu, Joyce
    Burris, Howard
    Wang, Judy S.
    Barroilhet, Lisa
    Gutierrez, Martin
    Wang, Yulei
    Vaze, Anjali
    Commerford, Renee
    Royer-Joo, Stephanie
    Choeurng, Voleak
    Humke, Eric
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 473 - 480
  • [43] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
    O'Malley, David M.
    Martin, Lainie P.
    Gilbert, Lucy
    Vergote, Ignace
    Matulonis, Ursula A.
    Birrer, Michael J.
    Castro, Cesar Martin
    Malek, Karim S.
    Gonzalez-Martin, Antonio
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
    Moore, K.
    Oza, A.
    Colombo, N.
    Oaknin, A.
    Scambia, G.
    Lorusso, D.
    Farias-Eisner, R.
    Banerjee, S.
    Murphy, C.
    Tanyi, J.
    Hirte, H.
    Konner, J.
    Lim, P.
    Hayes, M. Prasad
    Monk, B.
    Kim, S.
    Wang, J.
    Pautier, P.
    Vergote, I.
    Birrer, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
    Antonia, S. J.
    Brahmer, J. R.
    Khleif, S.
    Balmanoukian, A. S.
    Ou, S-H. I.
    Gutierrez, M.
    Kim, D-W.
    Kim, S-W.
    Ahn, M-J.
    Leach, J.
    Jamal, R.
    Jaeger, D.
    Jerusalem, G.
    Jin, X.
    Gupta, A.
    Antal, J.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
    Moore, Kathleen N.
    Martin, Lainie P.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Kirby, Maurice William
    Zhou, Yinghui
    Michenzie, Mary F.
    Ponte, Joseph
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.
    Moore, Kathleen N.
    Matulonis, Ursula A.
    O'Malley, David M.
    Konner, Jason A.
    Martin, Lainie P.
    Perez, Raymond P.
    Bauer, Todd Michael
    Gilbert, Lucy
    Seward, Shelly Marie
    Oza, Amit M.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer
    Huhe, Muren
    Lou, Jiaxin
    Zhu, Yumeng
    Zhao, Yu
    Shi, Ying
    Wang, Bo
    Sun, Xiuxuan
    Zhang, Xiaoqin
    Zhang, Yang
    Chen, Zhi-Nan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 513 (04) : 1083 - 1091
  • [49] UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer
    Richardson, Debra
    Concin, Nicole
    Hays, John
    Perez Fidalgo, Jose Alejandro
    Pothuri, Bhavana
    Banerjee, Susana
    Ghamande, Sharad
    Ray Coquard, Isabelle
    Germanova, Anna
    Rimel, Bobbie
    Lorusso, Domenica
    Cloven, Noelle
    Baurain, Jean-Francois
    Randall, Leslie
    Brasiuniene, Birute
    Tseng, Jill
    Klasa-Mazurkiewicz, Dagmara
    Werner, Theresa
    Oaknin, Ana
    Ang, Joo Ern
    Leary, Alexandra
    Bishop, Erin
    Marth, Christian
    Bradshaw, Chelsea
    Burger, Robert
    Gonzalez Martin, Antonio Jose
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S56 - S56
  • [50] Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients
    Terwogt, JMM
    van Tellingen, O
    Panday, VRN
    Huizing, MT
    Schellens, JHM
    Huinink, WWT
    Boschma, MUS
    Giaccone, G
    Veenhof, CHN
    Beijnen, JH
    ANTI-CANCER DRUGS, 2000, 11 (09) : 687 - 694
12345